In Asia, EC is the sixth most common cancer, with the region constituting almost 80% of the new EC cases globally. The highest standardized incidence rate has been observed in East Asia.
Novotech Announced as Finalist for Asia Pacific Cell & Gene Therapy CRO Excellence Awards 2023
Singapore - Novotech, the leading Asia Pacific centred biotech CRO with global e
Read more